blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3830125

EP3830125 - CHIMERIC ANTIGEN RECEPTOR THERAPY T CELL EXPANSION KINETICS AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  07.05.2021
Database last updated on 15.06.2024
FormerThe international publication has been made
Status updated on  08.02.2020
Formerunknown
Status updated on  06.09.2019
Most recent event   Tooltip12.06.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Kite Pharma, Inc.
2400 Broadway
Santa Monica, CA 90404 / US
[2021/23]
Inventor(s)01 / ROSSI, John M.
c/o Kite Pharma, Inc.
2400 Broadway
Santa Monica, California 90404 / US
02 / BOT, Adrian I.
c/o Kite Pharma, Inc.
2400 Broadway
Santa Monica, California 90404 / US
 [2021/23]
Representative(s)Schnappauf, Georg
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2021/23]
Application number, filing date19759453.401.08.2019
[2021/23]
WO2019US44638
Priority number, dateUS201862713994P02.08.2018         Original published format: US 201862713994 P
US201862756391P06.11.2018         Original published format: US 201862756391 P
[2021/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020028647
Date:06.02.2020
Language:EN
[2020/06]
Type: A1 Application with search report 
No.:EP3830125
Date:09.06.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 06.02.2020 takes the place of the publication of the European patent application.
[2021/23]
Search report(s)International search report - published on:EP06.02.2020
ClassificationIPC:C07K16/28, A61K35/17, A61K39/00, C07K14/725, G01N33/50
[2021/23]
CPC:
C07K16/2803 (EP,IL); A61K35/17 (IL,US); C12N5/0636 (EP,IL,KR,US);
A61K39/4611 (EP,IL,KR); A61K39/4631 (EP,IL,KR); A61K39/464412 (EP,IL,KR);
A61P35/00 (KR); C07K14/7051 (EP,IL); G01N33/57426 (EP,IL,KR);
C07K2317/622 (EP,IL,KR); C07K2319/03 (EP,IL); C07K2319/33 (EP,IL);
C12N2501/2301 (KR); C12N2501/2302 (EP,IL,US); C12N2510/00 (EP,IL,KR);
G01N2800/52 (EP,IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/23]
TitleGerman:T-ZELL-EXPANSIONSKINETIK FÜR CHIMÄRE ANTIGEN-REZEPTORTHERAPIE UND IHRE VERWENDUNGEN[2021/23]
English:CHIMERIC ANTIGEN RECEPTOR THERAPY T CELL EXPANSION KINETICS AND USES THEREOF[2021/23]
French:CINÉTIQUE D'EXPANSION DE LYMPHOCYTES T POUR THÉRAPIE PAR RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE ET SES UTILISATIONS[2021/23]
Entry into regional phase28.01.2021National basic fee paid 
28.01.2021Designation fee(s) paid 
28.01.2021Examination fee paid 
Examination procedure28.01.2021Amendment by applicant (claims and/or description)
28.01.2021Examination requested  [2021/23]
28.01.2021Date on which the examining division has become responsible
Fees paidRenewal fee
13.08.2021Renewal fee patent year 03
15.06.2022Renewal fee patent year 04
14.06.2023Renewal fee patent year 05
12.06.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XYI]US2016303166  (KATZ STEVEN C [US], et al);
 [X]US2017137783  (BEDOYA FELIPE [US], et al);
 [X]US2018022815  (CHANG LUNG-JI [US]);
 [X]WO2018132695  (CELDARA MEDICAL LLC [US], et al);
 [XY]US2018208671  (WANG QIONG J [US], et al);
by applicantUS5728388
 US5827642
 US6040177
 US6319494
 US2002006409
 US6797514
 US6867041
 US6905874
 WO2008081035
 US7741465
 WO2012079000
 WO2012129514
 US2013287748
 US2014050708
 US2014099309
 US2014154228
 US2014227237
 US19430622621
 US19500621677
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.